Literature DB >> 31857520

Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.

Mona Abdel-Halim Ibrahim1, Abdelrahman Mohamed1, Marwa Yassin Soltan1.   

Abstract

BACKGROUND: Hypopigmented mycosis fungoides is a rare variant of mycosis fungoides that may mimic many benign inflammatory hypopigmented dermatoses, and as yet there is no identified marker to differentiate between them. AIM: The aim of this study was to study the expression of thymocyte selection-associated high-mobility group box (TOX) in hypopigmented mycosis fungoides and one of its inflammatory mimickers (early active vitiligo) to assess its potential as a differentiating diagnostic marker.
METHODS: A case-control study was done using immunohistochemical analysis of TOX expression in 15 patients with hypopigmented mycosis fungoides and 15 patients with early active vitiligo. Immunohistochemical analysis was done via a semi-quantitative method and an image analysis method.
RESULTS: Hypopigmented mycosis fungoides showed a statistically significant higher expression of TOX than early active vitiligo. The expression of TOX was positive in a majority of hypopigmented mycosis fungoides cases (14 cases, 93.3%), while only one case (6.7%) of vitiligo was weakly positive. TOX also displayed 93.3% sensitivity and specificity, with a cut-off value of 1.5. LIMITATIONS: This was a pilot study testing hypopigmented mycosis fungoides against only a single benign inflammatory mimicker (early vitiligo). Other benign mimickers were not included.
CONCLUSION: Our findings showed that TOX expression can differentiate hypopigmented mycosis fungoides from early active vitiligo which is one of its benign inflammatory mimickers, with a high degree of sensitivity and specificity.

Entities:  

Keywords:  Cutaneous T-cell lymphoma; TOX; hypopigmented mycosis fungoides; oncogenesis; thymocyte selection–associated high-mobility group box; vitiligo

Mesh:

Substances:

Year:  2021        PMID: 31857520     DOI: 10.4103/ijdvl.IJDVL_1011_18

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  2 in total

1.  Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides.

Authors:  Tony T Jiang; Oleg Kruglov; Gloria H Y Lin; Angela Minic; Kimberly Jordan; Robert A Uger; Mark Wong; Yaping Shou; Oleg E Akilov
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

2.  TOX Expression in Mycosis Fungoides and Sezary Syndrome.

Authors:  Alessandro Pileri; Martina Cavicchi; Clara Bertuzzi; Simona Righi; Corrado Zengarini; Elena Sabattini; Giovanna Roncador; Claudio Agostinelli
Journal:  Diagnostics (Basel)       Date:  2022-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.